ABVC BioPharma Receives $50,000 in Licensing Fees from AiBtl BioPharma Inc.
ABVC BioPharma receives $50,000 in licensing fees from AiBtl BioPharma Inc., reinforcing confidence in therapeutic programs and positioning in growing markets.
This news matters because it highlights the financial backing and confidence in ABVC's therapeutic programs. The company's position in the growing MDD and ADHD markets is reinforced, with the potential for significant returns and value creation for investors.
